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Given the higher mortality rate of ICU patients with sepsis and AKI, we decided to investigate the possible correlation between
serum biomarkers of organ damage, and endotoxin activity in ICU septic patients. Ninety-eight consecutive adult patients were
enrolled in this study. Patients were divided in two groups depending on the presence of sepsis. Fifty-six patients had sepsis, while
forty-two patients were nonseptic. Among septic patients, twenty-four subjects developed AKI, while thirty-two did not. AKI
occurred in fourteen patients without sepsis as well. The levels of NGAL, BNP, and AOPP were signiﬁcantly higher among septic
patients compared with nonseptic subjects (P<0.001). Among septic patients, subjects who developed AKI showed signiﬁcant
higherlevelsofNGALandAOPP(P = 0.0425)andBNP(P = 0.0327).AmongpatientswhodevelopedAKI,asigniﬁcantdiﬀerence
was found only in terms of AOPP levels between septic and nonseptic patients. The correlation between endotoxin activity and
BNP in septic patients and the increase in the levels of NGAL, BNP, and AOPP in case of sepsis and AKI, in particular if they are
associated, indicate a multiorgan involvement in these two conditions.
1.Introduction
Sepsis, deﬁned as a systemic inﬂammatory response syn-
drome (SIRS) associated with an infectious disease [1, 2],
is a primary cause of morbidity and mortality in ICU [3]
and critically ill patients. Mortality rates range from 20% for
sepsis, to 40% for severe sepsis, to 60% for septic shock in
ICU patients [4].
Gram-negative bacteria are implicated in 50–60% of
sepsis, with Gram-positive bacteria accounting for a further
35–40% of cases. The remainder of causes are due to the less
common causes of fungi, viruses, and protozoa [5].
The heat-stable toxic component of Gram-negative bac-
teria, identiﬁed for the ﬁrst time by Pfeiﬀer at the end of
the 19th century [6, 7] and called “endotoxin”, is considered
to play an important role in the pathogenesis of septic
shock [8]. It causes the release of diﬀerent cytokines, such
as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-
α), and interacts with the complement pathway and the
coagulation system [8, 9].
Sepsis is also a contributing factor in more than 20% of
casesofacutekidneyinjury(AKI)inICUpatients,withcases
severe enough to require renal replacement therapy [10–12].
AKI occurs in 35–65% of ICU admissions, and most studies
show a threefold to ﬁvefold increase in the risk of death
among patients with AKI compared to patients without AKI.
Given the higher mortality rate of ICU patients with
sepsis and AKI, we decided to investigate the possible
correlation between serum biochemical markers of organ
damage, such as neutrophil gelatinase-associated lipocalin
(NGAL), advanced oxidation protein products (AOPP), and
brain natriuretic peptide (BNP) and endotoxin activity in
ICU septic patients. Moreover, comparisons of the levels of
these biomarkers were made between septic and nonseptic
patients, septic patients with or without AKI, and between
patients who developed AKI with or without sepsis.
2.MaterialandMethods
2.1. Study Population. Ninety-eight consecutive adult
patients, admitted to ICU of San Bortolo Hospital, Vicenza,
Italy, between October 2008 and august 2010, were enrolled
in this study. Patients were divided in two groups depending2 Critical Care Research and Practice
Table 1: Clinical and biochemical characteristics of septic patients.
Septic patients (N = 56)
Male sex (%) 33.9
Age (years) 69 (48.7 to 74.2)
Serum creatinine (mg/dL) 1.64 (1.04 to 2.97)
Temperature (◦Celsius) 36.4 ±2.0
WBC (million cells/mcL) 12.3 ±9.4
Platelets (103/μL) 144.6 ±110.9
pH 7.359 ±0.154
Na (mmol/L) 139.5 ±6.1
K (mmol/L) 4.2 ±1.1
PaO2/FiO2 (mmHg) 206.4 ±112.5
Sofa score 10 (8 to 12)
Died (%) 32.1
WBC: white blood cells; SOFA score: sequential organ failure assessment.
on the presence of sepsis, deﬁned as systemic inﬂammatory
response syndrome (SIRS) associated with an infectious
process. SIRS was considered to be present when at least
two of the following criteria were present: temperature
above 38◦Co rb e l o w3 6 ◦C, heart rate above 90beats/min,
respiratory rate above 20breaths/min or partial pressure
of carbon dioxide below 32mmHg, and white blood cell
count above 12,000mm3 or below 4,000mm3. Fifty-six
patients had sepsis, while forty-two patients were nonseptic.
Clinical and biochemical characteristic of septic patients are
summarized in Table 1.
Among septic patients, twenty-four subjects developed
AKI,deﬁnedbyRIFLEcriteria, whilethirty-twodid not. AKI
occurred in fourteen patients without sepsis as well.
Within four hours after admission blood samples were
taken for EAA (endotoxin activity assay), NGAL, and BNP
measurement. EDTA was used as an anticoagulant. Hep-
arinized blood samples were collected for AOPP evaluation.
Correlation between NGAL, AOPP, BNP and endotoxin
activity in septic patients was evaluated. Moreover, compar-
isons of the levels of these biomarkers were made between
septicandnonsepticpatients,septicpatientswithorwithout
AKI, and between patients who developed AKI with or
without sepsis.
2.2. Endotoxin Activity Assay (EAA). Serum endotoxin activ-
ity was measured by the EAAtm which measures the degree of
chemiluminescence of the circulating neutrophil population
induced by the exposure to endotoxin.
The test is based on the interaction between the endo-
toxin and a speciﬁc antiendotoxin antibody. Complement
components opsonize the endotoxin-antibody complex. The
opsonized immune complex primes neutrophils in the blood
to enhance their respiratory burst in response to zymosan.
The respiratory burst of the neutrophils yields oxidants
that react with luminal in the reaction mixture to emit
chemiluminescence.
The chemiluminescence can then be detected in a
photon-counting luminometer (SmartLine TL, Berthold
Detection Systems, Pforzheim, Germany).
A basal activity measurement (Tube 1) in the absence of
thespeciﬁcantiendotoxinantibodymeasuresthenonspeciﬁc
oxidative burst of the patient’s neutrophils. An additional
control measurement including the speciﬁc antiendotoxin
antibody and an excess of exogenous endotoxin (Tube 3)
measures the maximum oxidative burst of the patient’s
neutrophils. The test measurement (Tube 2) includes the
speciﬁc antibody to measure the neat level of endotoxin
activity. The EAAtm level is calculated by normalizing the
chemiluminescence in the test sample (Tube 2) against the
maximum chemiluminescence (Tube 3), correcting both
measurements for the basal activity chemiluminescence
(Tube 1).
Endotoxin activity levels are expressed as units on a scale
ranging from 0 to 1
0.00–0.39: EAAtm units: low endotoxin activity level,
0.40–0.59: EAAtm units: intermediate endotoxin
activity level,
≥0.60: EAAtm units: high endotoxin activity level.
2.3. NGAL and BNP Measurement. Plasma samples for
NGAL and BNP measurement were stored at minus
80 degrees Celsius to be analyzed subsequently. Plasma
NGAL and BNP were measured with ﬂuorescence-based
immunoassay with the Triage point-of-care analyzer (Biosite
Inc., San Diego, CA, USA), which allows a rapid quantitative
measurement of NGAL and BNP concentration in EDTA-
anticoagulated whole blood or plasma. NGAL and BNP
concentrations were expressed as nanograms per millilitre
(ng/mL) and pictograms per millilitre (pg/mL), respectively.
2.4. AOPP Measurement. AOPP levels were measured by
spectrophotometry and calibrated with Chloramine-T solu-
tions (Sigma Chemical Co., St. Louis, MO, USA), which
adsorb at 340nm in presence of potassium iodide. Two
hundred microliters of plasma diluted 1/5 in PBS, and 20μL
of acetic acid were mixed and calibrated versus the standard
reference of 200μL Chloramine-T solution (0–100μmol/L)
with 20μLo fa c e t i ca c i da n d1 0μL of potassium iodide.
The absorbance of the reaction mixture was read at
340nm against a blank containing 200μL of PBS, 10μLo f
potassium iodide, and 20μL of acetic acid. AOPP concentra-
tions were expressed as micromoles per liter of chloramine-T
equivalents (μmol/L).
2.5. Statistical Analysis. Statistical analysis was performed
with the use of SPSS software version 15.0. Categorical
variableswereexpressedaspercentages;continuousvariables
were expressed as means ± standard deviation (parametric
variables) or median (interquartile range; nonparametric
variable). Diﬀerences between groups were analyzed using
Student t-test and Mann-Whitney test as appropriate.
Correlation was performed with the use of the Spearman
rank coeﬃcient. Two-tailed probability values of <0.05 were
considered statistically signiﬁcant.Critical Care Research and Practice 3
Table 2: Comparison of biochemical markers between septic patients and nonseptic patients.
Septic pts (N = 56) Nonseptic pts (N = 42) P value
Male sex (%) 33.9 66.7 0.0013
Age (years) 69 (48.7 to 74.2) 67 (59 to 75) 0.83
Creatinine (mg/dL) 1.64 (1.04 to 2.97) 1.0 (0.8 to 1.0) <0.001
NGAL (ng/mL) 459 (213 to 744) 120 (79 to 174) <0.001
AOPP (μmol/L) 505.1 (307.6 to 643.5) 115.7 (79.2 to 181.7) <0.001
BNP (pg/mL) 409 (212 to 673) 135 (61 to 275) <0.001
S o f as c o r e 1 0( 8t o1 2 ) 5( 4t o5 ) <0.001
Died (%) 32.1 16.7 0.08
NGAL: neutrophil gelatinase-associated lipocalin; AOPP: advanced oxidation protein products; BNP: brain natriuretic peptide; SOFA score: sequential organ
failure assessment.
Table 3: Comparison of biochemical markers between AKI and No-AKI septic patients.
AKI septic pts (N = 24) No-AKI septic pts (N = 32) P value
Male sex (%) 29.2 37.5 0.51
Age (years) 69 (50 to 71) 69 (45 to 76) 0.63
Creatinine (mg/dL) 2.3 (1.5 to 3.4) 1.2 (0.8 to 1.9) 0.0065
NGAL (ng/mL) 572 (308 to 819) 321 (154 to 573) 0.0425
AOPP (μmol/L) 554.0 (366.8 to 717.6) 419.5 (286.8 to 607.4) 0.0425
BNP (pg/mL) 576 (291 to 1723) 348 (174 to 538) 0.0327
Sofa score 11 (8 to 13) 9 (7 to 12) 0.28
Died (%) 45.8 21.9 0.0575
NGAL: neutrophil gelatinase-associated lipocalin; AOPP: advanced oxidation protein products; BNP: brain natriuretic peptide; SOFA score: sequential organ
failure assessment.
3. Results
Septic patients were divided in three groups depending on
EAA levels. EAA < 40: 8 patients; EAA 40–60: 17 patients;
EAA > 60: 31 patients.
A signiﬁcant correlation (P = 0.02) was found only
between endotoxin activity and BNP levels of septic patients
(Figure 1). The levels of NGAL, BNP, and AOPP were
signiﬁcantly higher among septic patients compared with
nonseptic subjects (P<0.001) (Table 2). Among septic
patients, subjects who developed AKI showed signiﬁcant
higher levels of NGAL and AOPP (P = 0.0425) and BNP
(P = 0.0327) (Table 3). Among patients who developed AKI,
a signiﬁcant diﬀerence was found only in terms of AOPP
levels between septic and non septic patients (Table 4).
4. Discussion
As reported by Marshall et al., intermediate and high levels
of endotoxin activity are often found in ICU septic patients
[13], and they seem to correlate with the severity of the
disease,inparticularwiththehemodynamicalterations[14].
Sepsis, indeed, frequently causes cardiac abnormalities and
kidney dysfunction [15, 16] and, for this reason, can be
considered as an important cause of type 5 cardiorenal
syndrome [17].
In this study we investigated the possible correla-
tion between endotoxin activity in septic ICU patients and
biochemicalmarkersoforgandamage,suchasNGAL,AOPP,
and BNP.
As shown in Figure 1, a signiﬁcant correlation was
found only between endotoxin activity and BNP levels of
septic patients (P = 0.02). BNP is considered to be a
good diagnostic and prognostic biomarker, especially among
patients with congestive heart failure [18]. Elevated levels of
BNP are independent predictors of cardiovascular morbidity
and mortality, both in patients with normal and impaired
renal function, thus emphasizing the value of BNP in the
assessment of cardiorenal syndrome [19]. In our study,
intermediate and higher levels of endotoxin activity, which
predict an elevated risk for developing severe sepsis, were
associated with higher levels of BNP, which result from
cardiac dysfunction induced by sepsis.
We also compared the levels of NGAL, AOPP, and BNP
between septic and non septic patients, septic patients with
or without AKI, and between patients who developed AKI
with or without sepsis.
Serum NGAL has been shown to increase before serum
creatinine in case of acute kidney injury [20] and has
therefore become a novel early biomarker of acute renal
damage [21]. Moreover, it was found to rise in patients
with congestive heart failure, thus indicating a link between
cardiac dysfunction and renal injury [18, 22, 23].
Critically ill patients also present increased levels of
AOPP, induced by the overproduction of reactive oxygen
species (ROS) and the subsequent depletion of the antioxi-
dant endogenous stores. AOPP levels were demonstrated to4 Critical Care Research and Practice
Table 4: Comparison of biochemical markers between AKI septic patients and AKI nonseptic patients.
AKI septic pts (N = 24) AKI nonseptic pts (N = 14) P value
Male sex (%) 29.2 78.6 0.0033
Age (years) 69 (50 to 71) 76 (69 to 80) 0.0067
Creatinine (mg/dL) 2.3 (1.5 to 3.4) 1.0 (0.8 to 1.6) <0.001
NGAL (ng/mL) 572 (308 to 819) 312 (141 to 633) 0.15
AOPP (μmol/L) 554.0 (366.8 to 717.6) 118.9 (90.1 to 152.5) <0.001
BNP (pg/mL) 576 (291 to 1723) 305 (134 to 559) 0.1055
S o f as c o r e 1 1( 8t o1 3 ) 5( 5t o5 ) <0.001
Died (%) 45.8 42.9 0.85

























































Figure 1: Correlation between EAA (<0.40; 0.40–0.60; >0.60 units) and the levels of NGAL, BNP, and AOPP.
correlate with the risk to develop severe sepsis and with the
severity of AKI in ICU patients [19, 24].
In our study, the levels of NGAL, BNP, and AOPP were
signiﬁcantly higher among septic patients compared with
non septic subjects (P<0.001), as shown in Table 2.
Among septic patients, subjects who developed AKI showed
signiﬁcant higher levels of NGAL and AOPP (P = 0.0425)
and BNP (P = 0.0327) (Table 3). Among patients who
developed AKI, a signiﬁcant diﬀerence was found only in
terms of AOPP levels between septic and non septic patients
(Table 4).
These data suggest that sepsis and AKI are responsible
for the increase in the level of the three biomarkers, in
particular if they are associated. When limiting to the
AKI patients, there was no signiﬁcant diﬀerence in terms
of NGAL and BNP levels between septic and non septic
patients. The reason for this ﬁnding remains to be clariﬁed.
A possible explanation could be that renal damage alone can
cause a similar increase in the level of the two biomarkers,
independently on the presence of sepsis.
5. Conclusions
InsepticICUpatientsendotoxinactivitycorrelateswithBNP
levels. NGAL, AOPP, and BNP levels seem to be higher
in patients with sepsis and AKI, in particular if they are
associated. In case of AKI, a signiﬁcant diﬀerence between
septic and nonseptic patients was found only for AOPP
levels.
NGAL, AOPP, and BNP increase in case of sepsis, thus
indicating both cardiac and renal impairment. For this
reason, the rise in their levels in this condition can allow
clinicians to individualize patients at higher risk for de-
veloping severe sepsis and therefore at higher risk of death.
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